>Should GTC be evaluated like any other biotech, or should they be evaluated as a new platform for producting approved drugs at a lower price?<
GTC, not unlike any other company, will be evaluated on its potential to make a profit by whatever means ... if GTC remains a viable company. As of today, the jury is still out and the result is a nervous pps of 56 cents.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.